Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVATAK alone and with pembrolizumab in advanced solid tumors
NCT02043665Phase 1Completed
- Sponsor
- Viralytics Ltd
- Start
- Dec 2013
- Primary completion
- Jan 2020
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 3
01
Overview
Phase 1, open-label trial of coxsackievirus a21 in non-small cell lung cancer (NSCLC), bladder cancer, prostate cancer (PCa) and 1 more (2 arms), sponsored by Viralytics Ltd. Primary endpoint: Response rate assessed according to immune-related RECIST 1.1 criteria up to 6 months. Started Dec 2013; status: completed.
02
Drugs
coxsackievirus a21
03
Conditions
non-small cell lung cancer (NSCLC)bladder cancerprostate cancer (PCa)melanoma
Beyond the preview
Go deeper on NCT02043665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043665.